Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nuvalent ( (NUVL) ) has provided an announcement.
On December 9, 2025, Matthew Shair, Ph.D., resigned from the board of directors of Nuvalent, Inc., a decision not due to any disagreement with the company’s operations or policies. Subsequently, on December 10, 2025, Ron Squarer was elected as a new independent director, with compensation including stock options and restricted stock units valued at $600,000, marking a strategic addition to the board.
The most recent analyst rating on (NUVL) stock is a Buy with a $128.00 price target. To see the full list of analyst forecasts on Nuvalent stock, see the NUVL Stock Forecast page.
Spark’s Take on NUVL Stock
According to Spark, TipRanks’ AI Analyst, NUVL is a Neutral.
Nuvalent’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. Strengths include a solid cash position and no debt, while significant risks arise from the lack of revenue and dependency on external financing. Technical indicators suggest positive short-term momentum, but overbought conditions may present challenges. Valuation metrics are not favorable due to negative earnings.
To see Spark’s full report on NUVL stock, click here.
More about Nuvalent
Average Trading Volume: 584,973
Technical Sentiment Signal: Buy
Current Market Cap: $7.84B
See more data about NUVL stock on TipRanks’ Stock Analysis page.